62,799 Boston Scientific Corporation $BSX Shares Bought by Candriam S.C.A.

Candriam S.C.A. lifted its position in Boston Scientific Corporation (NYSE:BSX) by 17.1% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 430,284 shares of the medical equipment provider’s stock after acquiring an additional 62,799 shares during the period. Candriam S.C.A.’s holdings in Boston Scientific were worth $18,851,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Perigon Wealth Management LLC bought a new stake in shares of Boston Scientific in the 2nd quarter valued at about $883,000. Y Intercept Hong Kong Ltd grew its holdings in Boston Scientific by 148.8% during the second quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock worth $47,816,000 after purchasing an additional 670,060 shares during the period. Wealthfront Advisers LLC bought a new position in Boston Scientific during the second quarter worth about $3,253,000. PensionDanmark Pensionsforsikringsaktieselskab grew its holdings in Boston Scientific by 9.9% during the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock worth $13,659,000 after purchasing an additional 28,961 shares during the period. Finally, Tocqueville Asset Management L.P. acquired a new position in Boston Scientific during the second quarter worth approximately $38,539,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have issued reports on BSX shares. Oppenheimer lowered Boston Scientific from an “outperform” rating to a “market perform” rating in a research note on Thursday, October 29th. Truist Financial cut their price objective on Boston Scientific from $57.00 to $51.00 and set a “buy” rating for the company in a research report on Wednesday, October 14th. Citigroup reduced their target price on Boston Scientific from $48.00 to $44.00 and set a “neutral” rating for the company in a research note on Thursday, October 29th. Leerink Partners decreased their target price on Boston Scientific from $55.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, October 29th. Finally, TD Cowen cut Boston Scientific from a “buy” rating to a “hold” rating and dropped their price target for the company from $56.00 to $46.00 in a research note on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $61.43.

Boston Scientific Trading Up 0.2%

Shares of Boston Scientific stock opened at $42.82 on Monday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.81 and a current ratio of 1.36. The firm has a 50-day moving average of $44.32 and a 200-day moving average of $55.70. Boston Scientific Corporation has a 52-week low of $39.57 and a 52-week high of $105.65. The stock has a market cap of $62.06 billion, a PE ratio of 18.14, a PEG ratio of 1.27 and a beta of 0.60.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, hitting analysts’ consensus estimates of $0.73. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The business had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same period last year, the firm earned $0.75 earnings per share. Boston Scientific’s revenue for the quarter was up 1.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Boston Scientific Corporation will post 3.17 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts.

Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

Boston Scientific serves healthcare providers and patients around the world.